BR112022019881A2 - Métodos, população de células, composição e kit - Google Patents

Métodos, população de células, composição e kit

Info

Publication number
BR112022019881A2
BR112022019881A2 BR112022019881A BR112022019881A BR112022019881A2 BR 112022019881 A2 BR112022019881 A2 BR 112022019881A2 BR 112022019881 A BR112022019881 A BR 112022019881A BR 112022019881 A BR112022019881 A BR 112022019881A BR 112022019881 A2 BR112022019881 A2 BR 112022019881A2
Authority
BR
Brazil
Prior art keywords
methods
kit
composition
cell population
precursors
Prior art date
Application number
BR112022019881A
Other languages
English (en)
Portuguese (pt)
Inventor
Studer Lorenz
Kim Tae-Wan
Koo So-Yeon
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of BR112022019881A2 publication Critical patent/BR112022019881A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022019881A 2020-04-02 2021-04-02 Métodos, população de células, composição e kit BR112022019881A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063004138P 2020-04-02 2020-04-02
PCT/US2021/025596 WO2021203009A1 (en) 2020-04-02 2021-04-02 Methods of generating midbrain dopamine neurons, midbrain neurons and uses thereof

Publications (1)

Publication Number Publication Date
BR112022019881A2 true BR112022019881A2 (pt) 2022-11-22

Family

ID=77929755

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019881A BR112022019881A2 (pt) 2020-04-02 2021-04-02 Métodos, população de células, composição e kit

Country Status (12)

Country Link
US (1) US20230143486A1 (https=)
EP (1) EP4127137A4 (https=)
JP (2) JP2023520466A (https=)
KR (1) KR20220164012A (https=)
CN (1) CN115768875A (https=)
AU (1) AU2021248640A1 (https=)
BR (1) BR112022019881A2 (https=)
CA (1) CA3177525A1 (https=)
IL (1) IL296919A (https=)
MX (1) MX2022012366A (https=)
WO (1) WO2021203009A1 (https=)
ZA (1) ZA202211266B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023220639A2 (en) * 2022-05-10 2023-11-16 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for improved memory in the aging
US12565639B2 (en) 2023-06-13 2026-03-03 Aspen Neuroscience, Inc. Methods for differentiating dopaminergic neurons from stem cells
WO2025166063A1 (en) 2024-01-31 2025-08-07 Bluerock Therapeutics Lp Igfbp2 in cell culture
WO2025252180A1 (zh) * 2024-06-05 2025-12-11 中国科学院脑科学与智能技术卓越创新中心 中脑多巴胺能祖细胞群的体外制备方法
WO2026006245A1 (en) * 2024-06-25 2026-01-02 Bluerock Therapeutics Lp Three-dimensional culturing of pluripotent stem cells for improved differentiability

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3693455A1 (en) * 2011-11-04 2020-08-12 Memorial Sloan-Kettering Cancer Center Midbrain dopamine (da) neurons for engraftment
EP2614829A1 (en) * 2012-01-11 2013-07-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Mammalian neural plate border stem cells capable of forming neural tube and neural crest cell lineages including central and peripheral neurons
WO2014161075A1 (en) * 2013-04-05 2014-10-09 University Health Network Methods and compositions for generating chondrocyte lineage cells and/or cartilage like tissue
EP3498824A1 (en) * 2013-04-26 2019-06-19 Memorial Sloan-Kettering Cancer Center Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells
WO2017160234A1 (en) * 2016-03-14 2017-09-21 Agency For Science, Technology And Research Generation of midbrain-specific organoids from human pluripotent stem cells

Also Published As

Publication number Publication date
KR20220164012A (ko) 2022-12-12
WO2021203009A1 (en) 2021-10-07
US20230143486A1 (en) 2023-05-11
CN115768875A (zh) 2023-03-07
JP2025184905A (ja) 2025-12-18
IL296919A (en) 2022-12-01
CA3177525A1 (en) 2021-10-07
EP4127137A4 (en) 2024-05-22
JP2023520466A (ja) 2023-05-17
AU2021248640A1 (en) 2022-10-27
MX2022012366A (es) 2022-12-15
EP4127137A1 (en) 2023-02-08
ZA202211266B (en) 2023-05-31

Similar Documents

Publication Publication Date Title
BR112022019881A2 (pt) Métodos, população de células, composição e kit
BR112022003826A2 (pt) Métodos para gerar e isolar neurônios de dopamina do mesencéfalo, população celular, composição e kit
DOP2022000141A (es) Inhibidores de sarm1
CL2023000525A1 (es) Inhibidores de sarm1
ECSP22029193A (es) Aminas bicíclicas como inhibidoras de la cdk2
CL2024000856A1 (es) Composiciones de oligonucleótidos y métodos de estas
CO2022001453A2 (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
BR112022005711A2 (pt) Métodos e composições para tratar uma doença ou transtorno
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
BR112019024264A2 (pt) Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer
CL2020001349A1 (es) Compuestos, composición y uso de los mismos como moduladores de la expresión de pcsk9. (divisional solicitud 201902574)
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
MX2021007503A (es) Moduladores de la expresion de hsd17b13.
MX2024012807A (es) Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas
BRPI0812170A8 (pt) Moduladores de gama secretase
PE20210109A1 (es) Moduladores de la expresion de irf4
WO2018195110A8 (en) Regulation of ran translation by pkr and eif2a-p pathways
BR112015029327A2 (pt) Moduladores de oligonucleotídeo de linfoma 11a/cll de célula b (bcl11a) e usos dos mesmos
CO2024004970A2 (es) Agentes degradantes de tyk2 y sus usos
CL2020001851A1 (es) Moduladores de la expresión dnm2
MX2021010152A (es) Moduladores de la expresion de malat1.
BR112017024853A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um mamífero, para tratamento de prurido em um mamífero, para tratamento ou profilaxia e uso de um composto
MX2022000646A (es) Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms).
BR112023015590A2 (pt) Antagonistas de gpr84 e usos dos mesmos
BR112021023413A2 (pt) Método para prevenir a formação de depósitos calcificados e para inativar xenoantígenos em matrizes biológicas